DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
X• P••••••••• I••
Drug Discovery & Developmentgroup grade Aon a schedule nowsponsor unattributed
Also written as: 11; 11/26/2019; 2019; 26; Equity; Inc. and
Principal held
at least $75.0M
sum of BDC pieces, a lower bound
Fair value
$77.4M
100c on cost, debt pieces
Unfunded
n/a
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
2 equity pieces beside them
Next maturity
Jul 1, 2027
$75.0M inside 24 months
On the tape since
Dec 31, 2022
latest Jun 30, 2026
Events
6
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $75.0M | 100c | S+315 bp | Jul 1, 2027 | 1 |
Lenders
every BDC piece at the latest quarter end
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | term loan first lien Senior Secured, July 2027, Prime + 3.15%, Floor rate 10.15%, 3.72% Exit Fee | $75.0M | $77.2M 100c | S+315 bp |
| H••••••• C••••••• I••• | warrants equity Warrant, 3/18/2019, Common Stock | n/a | $8,000 2c | |
| H••••••• C••••••• I••• | equity equity Common Stock | n/a | $244,000 8c |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $75.0M | $77.2M | 100c | 0 |
| Mar 31, 2026 | 1 | $75.0M | $76.7M | 100c | 0 |
| Dec 31, 2025 | 1 | $150M | $153M | 100c | 0 |
| Sep 30, 2025 | 1 | $75.0M | $76.5M | 100c | 0 |
| Jun 30, 2025 | 1 | $75.0M | $73.7M | 97c | 0 |
| Mar 31, 2025 | 1 | $75.0M | $74.9M | 99c | 0 |
| Dec 31, 2024 | 1 | $75.0M | $75.7M | 100c | 0 |
| Sep 30, 2024 | 1 | $75.0M | $75.3M | 100c | 0 |
| Jun 30, 2024 | 1 | $75.0M | $75.3M | 100c | 0 |
| Mar 31, 2024 | 1 | $55.0M | $55.8M | 102c | 0 |
| Dec 31, 2023 | 1 | $110M | $111M | 101c | 0 |
| Sep 30, 2023 | 1 | $55.0M | $54.8M | 101c | 0 |
| Jun 30, 2023 | 1 | $32.5M | $32.7M | 100c | 0 |
| Mar 31, 2023 | 1 | $32.5M | $32.4M | 100c | 0 |
| Dec 31, 2022 | 1 | $32.5M | $33.7M | 100c | 0 |
What changed
- Maturity approachingJul 1, 2027
- Maturity approachingJul 1, 2027
- Maturity extended (observed)Jun 30, 2024
- Maturity extended (observed)Jun 30, 2024
- Maturity extended (observed)Dec 31, 2023
- Maturity extended (observed)Dec 31, 2023
- Spread changed (observed)Mar 31, 2023
- Maturity extended (observed)Mar 31, 2023
- Maturity extended (observed)Mar 31, 2023
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- X• P•••••••••derivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it